Proteostasis Therapeutics, Inc. (PTI): Price and Financial Metrics


Proteostasis Therapeutics, Inc. (PTI)

Today's Latest Price: $1.42 USD

0.00 (0.00%)

Updated Jun 2 4:00pm

Add PTI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

PTI Stock Summary

  • For PTI, its debt to operating expenses ratio is greater than that reported by only 0.34% of US equities we're observing.
  • PTI's price/sales ratio is 17.1; that's higher than the P/S ratio of 93.08% of US stocks.
  • The volatility of Proteostasis Therapeutics Inc's share price is greater than that of 95.32% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to PTI, based on their financial statements, market capitalization, and price volatility, are AFMD, GRTS, UMRX, ALPN, and SPRO.
  • Visit PTI's SEC page to see the company's official filings. To visit the company's web site, go to www.proteostasis.com.
PTI Daily Price Range
PTI 52-Week Price Range

PTI Stock Price Chart More Charts


PTI Price/Volume Stats

Current price $1.42 52-week high $4.72
Prev. close $1.42 52-week low $0.61
Day low $1.33 Volume 1,121,710
Day high $1.44 Avg. volume 1,383,908
50-day MA $1.43 Dividend yield N/A
200-day MA $1.47 Market Cap 74.05M

Proteostasis Therapeutics, Inc. (PTI) Company Bio


Proteostasis Therapeutics, Inc., a biopharmaceutical company, develops therapeutics to treat protein conformational diseases. The company offers disease-modifying therapeutics for cystic fibrosis; and also develops treatments for diseases caused by an imbalance in the proteostasis network and characterized by defects in protein folding, trafficking, and clearance, including genetic, neurodegenerative, and retinal degenerative diseases. The company was founded in 2006 and is based in Cambridge, Massachusetts.


PTI Latest News Stream


Event/TimeNews Detail
Loading, please wait...

PTI Latest Social Stream


Loading social stream, please wait...

View Full PTI Social Stream

Latest PTI News From Around the Web

Below are the latest news stories about Proteostasis Therapeutics Inc that investors may wish to consider to help them evaluate PTI as an investment opportunity.

Proteostasis Therapeutics' PTI-129 a potential COVID-19 candidate

Proteostasis Therapeutics (PTI) is up 21% premarket after announcing results from in vitro studies evaluating the use of PTI-129 as a treatment for COVID-19.PTI-129 is a pre-clinical, oral small molecule originally designed to treat protein misfolding disorders involving the unfolded protein response ((UPR)). In in vitro studies conducted at Calibr, the drug...

Seeking Alpha | June 1, 2020

Proteostasis Therapeutics Announces In Vitro Data for PTI-129 as Potential Treatment Candidate for COVID-19

Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced results from in vitro studies evaluating the use of PTI-129 as a treatment for COVID-19. PTI-129 is a pre-clinical, once-daily, oral small molecule originally designed to treat protein misfolding disorders involving the unfolded protein response (UPR).

Yahoo | June 1, 2020

Proteostasis Therapeutics (PTI) Reports Q1 Loss, Lags Revenue Estimates

Proteostasis (PTI) delivered earnings and revenue surprises of 17.39% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 15, 2020

Proteostasis Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced financial results for the first quarter ended March 31, 2020 and provided a corporate update.

Yahoo | May 15, 2020

Proteostasis Therapeutics to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced that Proteostasis management will present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 20, 2020 at 1:55 p.m. ET.

Yahoo | May 13, 2020

Read More 'PTI' Stories Here

PTI Price Returns

1-mo -7.19%
3-mo -12.88%
6-mo -62.53%
1-year 32.71%
3-year -67.65%
5-year N/A
YTD -37.72%
2019 -29.63%
2018 -44.43%
2017 -52.45%
2016 N/A
2015 N/A

Continue Researching PTI

Want to see what other sources are saying about Proteostasis Therapeutics Inc's financials and stock price? Try the links below:

Proteostasis Therapeutics Inc (PTI) Stock Price | Nasdaq
Proteostasis Therapeutics Inc (PTI) Stock Quote, History and News - Yahoo Finance
Proteostasis Therapeutics Inc (PTI) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.769 seconds.